K-Bio Proven by the Numbers: The Opening Act of Profit-Making Biotechs in 2025
Alteogen, Aimed Bio and Others Turn Profitable
Royalty and Milestone Income Becomes Visible
Last year, South Korea's bio industry entered a turning point, moving beyond mere expectations to proving its value with tangible results. Domestic biotech companies, which had long suffered from chronic deficits while relying only on news of technology exports, have begun to build self-sustaining revenue models by generating royalty income (technology usage fees) and milestones (stepwise technology payments.
According to the industry on the 19th, Alteogen posted sales of 202.1 billion won and operating profit of 114.8 billion won last year. Compared to the previous year, sales increased by 117%, and operating profit rose by 275%. The operating margin reached 57%. Royalties flowing in as the platform technology "ALT-B4," which is essential for developing a subcutaneous (SC) formulation of Merck (MSD)'s global blockbuster "Keytruda," entered a full-fledged commercialization track, drove the earnings growth. It is a representative case in which a single platform technology has demonstrated cash-generation capability that meets the global standard.
The old rule of the new drug development industry, where "survival despite deficits" was taken for granted, has been broken. Aimed Bio dispelled market concerns at once by delivering a "surprise performance" in its first year of listing. It recorded sales of 47.3 billion won and operating profit of 20.6 billion won last year, achieving an operating margin of 44%. As the technology export performance of its antibody-drug conjugate (ADC) pipeline became visible, upfront payments and milestones filled its coffers.
Onconic Therapeutics, which showcased the strength of an independently developed new drug, also made great strides. As "Zacubeau," the 37th domestically developed new drug for the treatment of gastroesophageal reflux disease, settled in the market and milestones flowed in following the successful completion of phase 3 clinical trials in China, sales surged to 53.4 billion won, nearly a 260% increase from the previous year, and operating profit reached 12.6 billion won, marking a turnaround to profitability. The company is regarded as having established an ideal "virtuous-cycle R&D structure," in which the money it earns is reinvested into the development of subsequent anticancer drugs. Kolon Life Science also achieved a turnaround to profitability, posting sales of 208.9 billion won and operating profit of 17.5 billion won.
Oscotec is likewise expected to emerge from its long tunnel of deficits. According to financial information provider FnGuide, Oscotec is highly likely to post a turnaround to profitability for the first time since 2020, having achieved sales of 46.3 billion won and operating profit of 6.3 billion won last year. The commercialization milestone for "Leclaza" to be received from Janssen is assessed to have contributed to this earnings turnaround. Medical AI company Thirona Technology recorded sales of 48.2 billion won and operating profit of 16.3 billion won, becoming the first listed domestic medical AI company to post an annual profit.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Ligachem Bio and ABL Bio are among the next-generation platform companies that also stood out. Ligachem Bio recorded sales of 141.6 billion won last year, as its ADC (antibody-drug conjugate) pipelines licensed out to major multinational pharmaceutical companies achieved milestones at each clinical stage. However, as clinical trial expenses increased due to the build-out of new pipelines, its operating loss expanded to 106.5 billion won. ABL Bio also received technology fees from Sanofi and others by leveraging its blood-brain barrier (BBB)-penetrating platform "Grabody-B," and achieved sales of 79.3 billion won last year, representing growth of more than 137% compared to the previous year. It is evaluated as having laid the groundwork for a turnaround to profitability through the inherent scalability of the platform, which generates simultaneous revenue from multiple pipelines.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.